This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Publicover, J.
Right arrow Articles by Rose, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Publicover, J.
Right arrow Articles by Rose, J. K.

 Previous Article  |  Next Article 

Journal of Virology, September 2004, p. 9317-9324, Vol. 78, No. 17
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.17.9317-9324.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Characterization of Nonpathogenic, Live, Viral Vaccine Vectors Inducing Potent Cellular Immune Responses

Jean Publicover,1,2 Elizabeth Ramsburg,2 and John K. Rose2*

Section of Microbial Pathogenesis,1 Department of Pathology, Yale University School of Medicine, New Haven, Connecticut2

Received 11 March 2004/ Accepted 16 April 2004

Experimental vaccines based on recombinant vesicular stomatitis viruses (VSV) expressing foreign viral proteins are protective in several animal disease models. Although these attenuated viruses are nonpathogenic in nonhuman primates when given by nasal, oral, or intramuscular routes, they are pathogenic in mice when given intranasally, and further vector attenuation may be required before human trials with VSV-based vectors can begin. Mutations truncating the VSV glycoprotein (G) cytoplasmic domain from 29 to 9 or 1 amino acid (designated CT9 or CT1, respectively) were shown previously to attenuate VSV growth in cell culture and pathogenesis in mice. Here we show that VSV recombinants carrying either the CT1 or CT9 deletion and expressing the human immunodeficiency virus (HIV) Env protein are nonpathogenic in mice, even when given by the intranasal route. We then carried out a detailed analysis of the CD8+ T-cell responses, including in vivo cytotoxic T-cell activity, induced by these vectors. When given by either the intranasal or intraperitoneal route, the VSV-CT9 vector expressing HIV Env elicited primary and memory CD8+ T-cell responses to Env equivalent to those elicited by recombinant wild-type VSV expressing Env. The VSV-CT1 vector also induced potent CD8+ T-cell responses after intraperitoneal vaccination, but was less effective when given by the intranasal route. The VSV-CT1 vector was also substantially less effective than the VSV-CT9 or wild-type vector at inducing antibody to Env. The VSV-CT9 vector appears ideal because of its lack of pathogenesis, propagation to high titers in vitro, and stimulation of strong cellular and humoral immune responses.


* Corresponding author. Mailing address: Department of Pathology, Yale University School of Medicine, 310 Cedar St. (BML 342), New Haven, CT 06510. Phone: (203) 785-6794. Fax: (203) 785-7467. E-mail: john.rose{at}yale.edu.


Journal of Virology, September 2004, p. 9317-9324, Vol. 78, No. 17
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.17.9317-9324.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Liao, J. B., Publicover, J., Rose, J. K., DiMaio, D. (2008). Single-Dose, Therapeutic Vaccination of Mice with Vesicular Stomatitis Virus Expressing Human Papillomavirus Type 16 E7 Protein. CVI 15: 817-824 [Abstract] [Full Text]  
  • Rose, N. F., Publicover, J., Chattopadhyay, A., Rose, J. K. (2008). Hybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectors. Proc. Natl. Acad. Sci. USA 105: 5839-5843 [Abstract] [Full Text]  
  • Cooper, D., Wright, K. J., Calderon, P. C., Guo, M., Nasar, F., Johnson, J. E., Coleman, J. W., Lee, M., Kotash, C., Yurgelonis, I., Natuk, R. J., Hendry, R. M., Udem, S. A., Clarke, D. K. (2008). Attenuation of Recombinant Vesicular Stomatitis Virus-Human Immunodeficiency Virus Type 1 Vaccine Vectors by Gene Translocations and G Gene Truncation Reduces Neurovirulence and Enhances Immunogenicity in Mice. J. Virol. 82: 207-219 [Abstract] [Full Text]  
  • Bukreyev, A., Rollin, P. E., Tate, M. K., Yang, L., Zaki, S. R., Shieh, W.-J., Murphy, B. R., Collins, P. L., Sanchez, A. (2007). Successful Topical Respiratory Tract Immunization of Primates against Ebola Virus. J. Virol. 81: 6379-6388 [Abstract] [Full Text]  
  • Simon, I. D., Publicover, J., Rose, J. K. (2007). Replication and Propagation of Attenuated Vesicular Stomatitis Virus Vectors In Vivo: Vector Spread Correlates with Induction of Immune Responses and Persistence of Genomic RNA. J. Virol. 81: 2078-2082 [Abstract] [Full Text]  
  • Bukreyev, A., Skiadopoulos, M. H., Murphy, B. R., Collins, P. L. (2006). Nonsegmented negative-strand viruses as vaccine vectors.. J. Virol. 80: 10293-10306 [Full Text]  
  • Publicover, J., Ramsburg, E., Robek, M., Rose, J. K. (2006). Rapid Pathogenesis Induced by a Vesicular Stomatitis Virus Matrix Protein Mutant: Viral Pathogenesis Is Linked to Induction of Tumor Necrosis Factor Alpha. J. Virol. 80: 7028-7036 [Abstract] [Full Text]  
  • Natuk, R. J., Cooper, D., Guo, M., Calderon, P., Wright, K. J., Nasar, F., Witko, S., Pawlyk, D., Lee, M., DeStefano, J., Tummolo, D., Abramovitz, A. S., Gangolli, S., Kalyan, N., Clarke, D. K., Hendry, R. M., Eldridge, J. H., Udem, S. A., Kowalski, J. (2006). Recombinant Vesicular Stomatitis Virus Vectors Expressing Herpes Simplex Virus Type 2 gD Elicit Robust CD4+ Th1 Immune Responses and Are Protective in Mouse and Guinea Pig Models of Vaginal Challenge. J. Virol. 80: 4447-4457 [Abstract] [Full Text]  
  • Ramsburg, E., Publicover, J., Buonocore, L., Poholek, A., Robek, M., Palin, A., Rose, J. K. (2005). A Vesicular Stomatitis Virus Recombinant Expressing Granulocyte-Macrophage Colony-Stimulating Factor Induces Enhanced T-Cell Responses and Is Highly Attenuated for Replication in Animals. J. Virol. 79: 15043-15053 [Abstract] [Full Text]  
  • Publicover, J., Ramsburg, E., Rose, J. K. (2005). A Single-Cycle Vaccine Vector Based on Vesicular Stomatitis Virus Can Induce Immune Responses Comparable to Those Generated by a Replication-Competent Vector. J. Virol. 79: 13231-13238 [Abstract] [Full Text]